FDA Approves First New Gonorrhea Treatments in 30 Years | Oral Antibiotics Available Now

The landscape of sexually transmitted infection (STI) treatment has shifted with the recent approval of two new oral antibiotics for gonorrhea: gepotidacin, marketed as Blujepa, and zoliflodacin, sold under the name Nuzolvence. These approvals, granted by the US Food and Drug Administration (FDA) in late 2025, represent the first completely new treatment options for gonorrhea in over three decades, arriving at a critical juncture as antibiotic resistance continues to rise globally. Gonorrhea, a common bacterial STI, affects an estimated 82 million people worldwide annually, with approximately 1.6 million cases reported each year in the United States alone.

The Growing Challenge of Antibiotic Resistance

For years, gonorrhea has demonstrated a remarkable ability to evolve and evade treatment. The bacterium responsible for the infection has developed resistance to a succession of antibiotics, including sulfanilamides, penicillins, tetracyclines, and fluoroquinolones. This left cephalosporins, specifically ceftriaxone administered via injection, as the primary and often sole effective treatment. However, even cephalosporins are showing signs of diminishing effectiveness, prompting urgent calls for new therapeutic strategies. The emergence of resistance isn’t simply a matter of individual treatment failures; it threatens to render gonorrhea untreatable, with potentially serious health consequences, including infertility in both men and women.

Blujepa (Gepotidacin): A New Pill for a Persistent Problem

Gepotidacin, now available as Blujepa, offers a new approach to tackling gonorrhea. Initially approved in March for treating urinary tract infections, its expanded approval for gonorrhea provides a much-needed oral alternative to the traditional injection. A standard course of treatment involves eight pills taken in two doses. Clinical trials involving 628 patients demonstrated comparable efficacy to the current standard treatment. Specifically, 93% of patients treated with Blujepa achieved a cure, compared to 91% of those receiving ceftriaxone plus azithromycin. While patients taking Blujepa reported a higher incidence of side effects – primarily diarrhea and nausea – these were generally mild in nature.

Nuzolvence (Zoliflodacin): A Single-Dose Solution

Nuzolvence, or zoliflodacin, presents another innovative treatment option. This medication is designed to be dissolved in water and administered as a single dose, potentially improving patient adherence. A study of 930 patients showed a cure rate of 91% at the one-week mark for those treated with Nuzolvence, compared to 96% for the standard treatment regimen. While slightly lower than the current standard, the single-dose convenience and novel mechanism of action are significant advantages.

A Collaborative Effort to Combat Resistance

The development of Nuzolvence is particularly noteworthy due to its origins. It was born from a partnership between the Global Antibiotic Research and Development Partnership (GARDP) – a non-profit organization established by the World Health Organization – and Innoviva Specialty Therapeutics. GARDP was specifically created to address the economic challenges associated with antibiotic development, as these drugs often lack the profit potential of treatments for chronic conditions. This collaborative model highlights a growing recognition of the demand for public-private partnerships to tackle the global threat of antibiotic resistance. The deliberate focus on gonorrhea as the sole target for Nuzolvence is a strategic move to prevent overuse and minimize the development of further resistance.

What Does This Mean for Patients and Public Health?

The arrival of these new antibiotics is being met with cautious optimism by public health experts. Edward Hook, MD, an emeritus professor of medicine at the University of Alabama and former ASHA board member, emphasized the significance of these approvals, stating that having new oral antibiotics effective against antibiotic-resistant gonorrhea is a “great addition to care for persons with an at risk for STIs.” The oral administration of both drugs offers a significant advantage over the current injection-based treatment, potentially improving patient convenience and access to care. However, it’s crucial to remember that these are not a panacea. Continued surveillance of antibiotic resistance patterns and responsible antibiotic stewardship remain essential to preserving the effectiveness of these and future treatments.

Looking Ahead: Surveillance, Stewardship, and Continued Research

The FDA approval of gepotidacin and zoliflodacin marks an vital step forward, but the fight against gonorrhea is far from over. Ongoing surveillance programs, such as those conducted by the Centers for Disease Control and Prevention (CDC), are vital for tracking the emergence of new resistance mechanisms and informing treatment guidelines. The CDC provides detailed guidance on the treatment of gonorrhea, which is regularly updated based on the latest scientific evidence. Continued research into new antibiotics and alternative treatment strategies is crucial to staying ahead of the evolving bacterium. Public health officials will be closely monitoring the real-world effectiveness of Blujepa and Nuzolvence, as well as any potential for the development of resistance to these new drugs. The success of these new therapies will depend not only on their efficacy but as well on responsible prescribing practices and a commitment to preventing the spread of gonorrhea through education and access to testing and treatment.